Icon Genetics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.icongenetics.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Recombinant, Bivalent, Norovirus Vaccine Study
Phase 1
Completed
- Conditions
- Norovirus
- Interventions
- Biological: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)Biological: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)Drug: Placebo
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Icon Genetics GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT05508178
- Locations
- 🇧🇪
Center for Vaccinology (CEVAC), Ghent University and University Hospital, Ghent, Belgium
Autologous Vaccine for Follicular Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, Follicular
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Icon Genetics GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT01022255
News
No news found